Prevalence of BER gene polymorphisms in sporadic breast cancer

• Published in: Oncology reports Vol. 19; no. 4; pp. 1033 - 1038
• Main Authors: ALI, Mohamedf, MEZA, Jane L, ROGAN, Eleanor G, CHAKRAVARTI, Dhrubajyoti
• Format: Journal Article
• Language: English
• Published: Athens S.n. 01.04.2008
• Subjects: Biological and medical sciences; Breast Neoplasms - genetics; DNA Repair - genetics; DNA-(Apurinic or Apyrimidinic Site) Lyase - genetics; DNA-Binding Proteins - genetics; Female; Genotype; Gynecology. Andrology. Obstetrics; Humans; Mammary gland diseases; Medical sciences; Polymorphism, Genetic; Tumors; X-ray Repair Cross Complementing Protein 1; Breast disease; Prevalence; Genetic variability; Sporadic; PARP1; APE1; Genotype; XRCC1; Breast cancer; LIG3; Malignant tumor; Epidemiology; Repair gene; Mammary gland diseases; Cancerology; Cancer; Polymorphism
• ISSN: 1021-335X; 1791-2431
• DOI: 10.3892/or.19.4.1033

Studies suggest that breast cancer is initiated by the induction of somatic mutations from errors in the base excision repair (BER) of endogenous estrogen-induced abasic sites. If so, the inheritance of certain polymorphic mutations in BER genes involved in the incorporation and management of such errors should increase the risk of breast cancer. To test this hypothesis, we examined breast tissues from 48 women (controls, histopathologically normal tissue from reduction mammoplasty) and 40 women with breast cancer (breast tumor-adjacent, histopathologically normal tissues) for the presence of reported polymorphic mutations in four BER genes. The breast tissues were obtained from the Cooperative Human Tissue Network-western division and from the University of Nebraska Medical Center. Using PCR-RFLP procedures, the XRCC1 gene was examined for Arg194Trp and Arg399Gln, APE1 for Asp148Glu, LIG3alpha for Arg780His and PARP1 for Pro377Ser mutations. The women in this study carried only the XRCC1 Arg399Gln polymorphism. This result was surprising because APE1 148Glu was reported to be frequently inherited (allele frequency, 0.47-0.495) by USA and European women. Thus, the USA women in our study are genetically different from those in the previous studies. Among the control women, 21 (43.75%) were Arg/Arg wild-types, 20 (41.67%) were Arg/Gln heterozygotes and 7 (14.6%) were Gln/Gln homozygotes. Among the breast cancer cases, 11 (27.5%) were Arg/Arg wild-types, 16 (40%) were Arg/Gln heterozygotes and 13 (32.5%) were Gln/Gln homozygotes. Thus, the Gln allele was significantly more frequent in breast cancer cases (allele frequency, 0.52) than in controls (allele frequency, 0.35), suggesting that XRCC1 399Gln may enhance the risk of breast cancer.